We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Dutch biotechnology company Crucell and allied contract manufacturer DSM Biologics have signed a PER.C6 research license agreement with Danish biotechnology company Symphogen.
Inovio Biomedical and Vical announced the initiation of a human Phase I study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma.
Samaritan Pharmaceuticals announced that it has begun the Phase II monotherapy trial of its lead "oral entry inhibitor" antiviral agent SP01A in HIV-infected patients.
Critical Therapeutics announced that their Phase II study of ZYFLO Filmtab (zileuton tablets) in patients with moderate to severe inflammatory facial acne did not show statistical significance in its primary efficacy endpoint.
Alexion Pharmaceuticals announced that it has completed randomization of its Phase III TRIUMPH efficacy trial of eculizumab, a monoclonal antibody drug that blocks the terminal complement part of the immune system, in patients with the chronic orphan blood disorder Paroxysmal Nocturnal Hemoglobinuria (PNH).
OSI Pharmaceuticals has received Canadian approval Tarceva as a treatment for advanced or spreading lung cancer in patients who have not responded to chemotherapy.
Perlegen Sciences is conducting a high-density, whole genome association study of bipolar disorder (BPD) in collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium (PNDRC).
Dutch biotechnology company Crucell N.V. announced plans for the clinical development of its combination of two human monoclonal antibodies against rabies, discovered last year using MAbstract technology.